Free Access
Méd. Intensive Réa.
Volume 26, Number 1, Janvier 2017
Page(s) 63 - 74
Section Mise au point / Update
Published online 19 December 2016
  • Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M, (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64: 73–84 [CrossRef] [PubMed] [Google Scholar]
  • Buzzetti E, Pinzani M, Tsochatzis EA, (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65: 1038–1048 [CrossRef] [PubMed] [Google Scholar]
  • Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ, (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592–1609 [CrossRef] [PubMed] [Google Scholar]
  • Ahmed A, Wong RJ, Harrison SA, (2015) NAFLD review: Diagnosis, treatment and outcomes. Clin Gastroenterolo Hepatol 13: 2062–2070 [CrossRef] [Google Scholar]
  • Bedossa P, (2016) Histological assessment of NAFLD. Dig Dis Sci 61: 1348–1355 [CrossRef] [PubMed] [Google Scholar]
  • Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA, (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249–1253 [CrossRef] [PubMed] [Google Scholar]
  • Patel YA, Berg CL, Moylan CA, (2016) Nonalcoholic Fatty liver disease: Key considerations before and after transplantation. Dig Dis Sci 61: 1406–1416 [CrossRef] [PubMed] [Google Scholar]
  • Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A, (2016) Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31: 936–944 [CrossRef] [PubMed] [Google Scholar]
  • Eckel RH, Alberti KG, Grundy SM, Zimmet PZ, (2010) The metabolic syndrome. The Lancet 375: 181–183 [CrossRef] [Google Scholar]
  • Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Söderberg S, Alberti KG, Tuomilehto J, Chitson P, Shaw JE, (2008) Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity 16: 2707–2716 [CrossRef] [Google Scholar]
  • Dhindsa S, Tripathy D, Sanalkumar N, RaviShankar S, Ghanim H, Aljada A, Dandona P, (2005) Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment. J Clin Endocrinol Metab 90: 5058–5063 [CrossRef] [PubMed] [Google Scholar]
  • Mowery NT, Dortch MJ, Dossett LA, Norris PR, Diaz JJ Jr, Morris JA Jr, May AK, (2009) Insulin resistance despite tight glucose control is associated with mortality in critically ill surgical patients. J Intensive Care 24: 242–251 [CrossRef] [Google Scholar]
  • Finney SJ, Zekveld C, Elia A, Evans TW, (2003) Glucose control and mortality in critically ill patients. JAMA 290: 2041–2047 [CrossRef] [PubMed] [Google Scholar]
  • Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, (2003) Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 31: 359–366 [CrossRef] [PubMed] [Google Scholar]
  • Byrne CD, Targher G, (2015) NAFLD: a multisystem disease. J Hepatol 62: S47–S64 [CrossRef] [PubMed] [Google Scholar]
  • Mantovani A, Ballestri S, Lonardo A, Targher G, (2016) Cardiovascular disease and myocardial abnormalities in nonalcoholic liver disease. Dig Dis Sci 61: 1246–1267 [CrossRef] [PubMed] [Google Scholar]
  • Anstee QM, Targher G, Day CP, (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10: 330–344 [CrossRef] [PubMed] [Google Scholar]
  • Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G, (2014) Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20: 1724–1745 [CrossRef] [PubMed] [Google Scholar]
  • Hamirani YS, Pandey S, Rivera JJ, Ndumele C, Budoff MJ, Blumenthal RS, Nasir K, (2008) Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 201: 1–7 [CrossRef] [PubMed] [Google Scholar]
  • Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K, (2013) A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 230: 258–267 [CrossRef] [PubMed] [Google Scholar]
  • Stepanova M, Younossi ZM, (2012) Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10: 646–650 [CrossRef] [PubMed] [Google Scholar]
  • Arslan U, Türkoğlu S, Balcioğlu S, Tavil Y, Karakan T, Cengel A, (2007) Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 18: 433–436 [CrossRef] [PubMed] [Google Scholar]
  • Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu cm, Yu J, Chan FK, Sung JJ, Chan HL, (2011) Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60: 1721–1727 [CrossRef] [PubMed] [Google Scholar]
  • Kim D, Kim WR, Kim HJ, Therneau TM, (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57: 1357–1365 [CrossRef] [PubMed] [Google Scholar]
  • Sinner MF, Wang N, Fox CS, Fontes JD, Rienstra M, Magnani JW, Vasan RS, Calderwood AH, Pencina M, Sullivan LM, Ellinor PT, Benjamin EJ, (2013) Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 111: 219–224 [CrossRef] [PubMed] [Google Scholar]
  • Alonso A, Misialek JR, Amiin MA, Hoogeveen, RC, Chen LY, Agarwal SK, Loehr LR, Soliman EZ, Selvin E, (2014) Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 100: 1151–1156 [CrossRef] [PubMed] [Google Scholar]
  • Ozveren O, Izgi C, Eroglu E, Simsek MA, Turer A, Kucukdurmaz Z, Cinar V, Degertekin M, (2016) Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty liver disease. Ultrason Imaging 38: 225–235 [CrossRef] [PubMed] [Google Scholar]
  • Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, Chiu HM, Lin HJ, Ho YL, Yang WS, Wu MS, Chen MF, (2015) Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc 4: e001820 [CrossRef] [PubMed] [Google Scholar]
  • Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM, (2010) TNF-alpha and IL-1beta increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium 47: 378–386 [CrossRef] [PubMed] [Google Scholar]
  • Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E, (2011) Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 22: 660–670 [CrossRef] [PubMed] [Google Scholar]
  • Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G, (1998) Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27: 28–34 [CrossRef] [PubMed] [Google Scholar]
  • Bonapace S, Valbusa F, Bertolini L, Pichri I, Mantovani A, Rossi A, Zenari L, Barbieri E, Targher G, (2014) Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One 9: e88371 [CrossRef] [PubMed] [Google Scholar]
  • Markus MR, Baumeister SE, Stritzke J, Dörr M, Wallaschofski H, Völzke H, Lieb W, (2013) Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol 33: 1690–1695 [CrossRef] [PubMed] [Google Scholar]
  • Völzke H, Haring R, Lorbeer R, Wallaschofski H, Reffelmann T, Empen K, Rettig R, John U, Felix SB, Dörr M, (2010) Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis 209: 606–610 [CrossRef] [PubMed] [Google Scholar]
  • Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho GY, Baik I, Lim HE, Kim EJ, Na JO, Lee JB, Lee SK, Shin C, (2014) Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100: 938–943 [CrossRef] [PubMed] [Google Scholar]
  • Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S, (2006) Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40: 949–955 [CrossRef] [PubMed] [Google Scholar]
  • Van Wagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, Rinella ME, Shah SJ, (2015) Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 62: 773–783 [CrossRef] [PubMed] [Google Scholar]
  • Granér M, Nyman K, Siren R, Pentikäinen MO, Lundbom J, Hakkarainen A, Lauerma K, Lundbom N, Nieminen MS, Taskinen MR, (2015) Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ Cardiovasc Imaging 8: e001979 [CrossRef] [PubMed] [Google Scholar]
  • Rijzewijk LJ, Van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, De Roos A, Lamb HJ, (2008) Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 52: 1793–1799 [CrossRef] [PubMed] [Google Scholar]
  • Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, Ragogna F, Canu T, Scifo P, Del Mashio A, Luzi L, (2008) Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47: 51–58 [CrossRef] [PubMed] [Google Scholar]
  • Fintini D, Chinali M, Cafiero G, Esposito C, Giordano U, Turchetta A, Pescosolido S, Pongiglione G, Nobili V, (2014) Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutr Metab Cardiovasc Dis 24: 72–74 [CrossRef] [PubMed] [Google Scholar]
  • Sunbul M, Kivrak T, Durmus E, Akin H, Aydin Y, Ergelen R, Yilmaz Y, Agirbasli M, (2015) Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc Ther 33: 294–299 [CrossRef] [PubMed] [Google Scholar]
  • Poloz Y, Stambolic V, (2015) Obesity and cancer, a case for insulin signaling. Cell Death and Disease 6: e2037 [CrossRef] [Google Scholar]
  • Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ, (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625–1638 [CrossRef] [PubMed] [Google Scholar]
  • Angulo P, Kleiner De, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F, (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterol 149: 389–397 [CrossRef] [Google Scholar]
  • Arase Y, Suzuki F, Kobayashi M, Kawamura Y, Matsumoto N, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kato K, Tanabe M, Ogawa K, Hara S, Kobayashi T, (2011) The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 50: 1081–1087 [CrossRef] [PubMed] [Google Scholar]
  • Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M, (2010) Relationship between kidney function and liver histology in subjects withnonalcoholic steatohepatitis. Clin J Am Soc Nephrol 5: 2166–2171 [CrossRef] [PubMed] [Google Scholar]
  • Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM, (2007) Effects of bariatric surgery on mortality in Swedish obese subjects N Engl J Med 357: 741–752 [CrossRef] [PubMed] [Google Scholar]
  • Lassailly G, Caiazzo R, Buob, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P, (2015) Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterol 149: 379–388 [CrossRef] [Google Scholar]
  • Hannah WN, Harrison SA, (2016) Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig Dis Sci 61: 1365–1374 [CrossRef] [PubMed] [Google Scholar]
  • Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM, (2015) Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg 19: 429–436 [CrossRef] [PubMed] [Google Scholar]
  • Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK, (2008) Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 6: 1396–1402 [CrossRef] [PubMed] [Google Scholar]
  • Ratziu V, (2016) Novel pharmacotherapy options for Nash. Dig Dis Sci 61: 1398–1405 [CrossRef] [PubMed] [Google Scholar]
  • Laganà AS, Vitale SG, Nigro A, Sofo V, Salmeri FM, Rossetti P, Chiara Rapisarda AM, La Vignera S, Condorelli RS, Rizzo G, Buscema M, (2016) Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives Int J Mol Sci 17: pii:E999 [Google Scholar]
  • Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, on behalf of the GOLDEN-505 Investigator Study Group (2016) Elafibranor, an agonist of the peroxisome proliferator-activated receptor alpha and delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150: 1147–1159 [CrossRef] [PubMed] [Google Scholar]
  • Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, (2015) NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385: 956–965 [CrossRef] [PubMed] [Google Scholar]
  • Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K; LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN, (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicenter, double-blind, randomized, placebo-controlled phase 2 study. Lancet 387: 679–690 [CrossRef] [PubMed] [Google Scholar]
  • Lassailly G, Caiazzo R, Pattou F, Mathurin P, (2016) Perspectives on treatment for nonalcoholic steatohepatitis. Gastroenterol 150: 1835–1848 [CrossRef] [Google Scholar]
  • Afzali A, Berry K, Ioannou GN, (2012) Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 18: 29–37 [CrossRef] [PubMed] [Google Scholar]
  • Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y, (2014) Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12: 394–402 [CrossRef] [PubMed] [Google Scholar]
  • Park CW, Tsai NT, Wong LL, (2011) Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 25: E606–11 [CrossRef] [PubMed] [Google Scholar]
  • Fussner LA, Charlton MR, Heimbach JK, Fan C, Dierkhising R, Coss E, Watt KD, (2014) [Google Scholar]
  • The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int 34: 1259–1266 [Google Scholar]
  • Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A, (2010) Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol 105: 613–620 [CrossRef] [Google Scholar]
  • Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, Upton MP, Reyes JD, Perkins JD, (2010) The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 16: 874–884 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.